ABL Bio Inc (298380) - Total Liabilities

Latest as of March 2026: ₩114.79 Billion KRW ≈ $77.79 Million USD

Based on the latest financial reports, ABL Bio Inc (298380) has total liabilities worth ₩114.79 Billion KRW (≈ $77.79 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

ABL Bio Inc - Total Liabilities Trend (2016–2025)

This chart illustrates how ABL Bio Inc's total liabilities have evolved over time, based on quarterly financial data. See 298380 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

ABL Bio Inc Competitors by Total Liabilities

The table below lists competitors of ABL Bio Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Brickworks Ltd AU:BKW	Australia	AU$2.45 Billion
Offshore Oil Engineering Co Ltd SHG:600583	China	CN¥19.20 Billion
Orion Corp KO:271560	Korea	₩630.78 Billion
Aditya Birla Sun Life AMC Limited NSE:ABSLAMC	India	Rs3.74 Billion
Blue Star Limited NSE:BLUESTARCO	India	Rs51.31 Billion
OCI Co Ltd KO:010060	Korea	₩3.21 Trillion
MiTAC Holdings Corp TW:3706	Taiwan	NT$44.14 Billion
Hinge Health, Inc. NYSE:HNGE	USA	$366.23 Million

Liability Composition Analysis (2016–2025)

This chart breaks down ABL Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ABL Bio Inc stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.70	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.64	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.39	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ABL Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ABL Bio Inc (2016–2025)

The table below shows the annual total liabilities of ABL Bio Inc from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	₩124.24 Billion ≈ $84.19 Million	+92.03%
2024-12-31	₩64.70 Billion ≈ $43.84 Million	-24.83%
2023-12-31	₩86.07 Billion ≈ $58.33 Million	-25.59%
2022-12-31	₩115.67 Billion ≈ $78.39 Million	+1117.57%
2021-12-31	₩9.50 Billion ≈ $6.44 Million	+2.93%
2020-12-31	₩9.23 Billion ≈ $6.25 Million	-15.28%
2019-12-31	₩10.89 Billion ≈ $7.38 Million	-8.50%
2018-12-31	₩11.91 Billion ≈ $8.07 Million	-88.80%
2017-12-31	₩106.32 Billion ≈ $72.05 Million	+441.66%
2016-12-31	₩19.63 Billion ≈ $13.30 Million	--

About ABL Bio Inc

KQ:298380 Korea Biotechnology

Market Cap

$3.58 Billion

₩5.29 Trillion KRW

Market Cap Rank

#4509 Global

#113 in Korea

Share Price

₩95900.00

Change (1 day)

+5.27%

52-Week Range

₩61800.00 - ₩245500.00

All Time High

₩245500.00